Fairvalue-Calculator Fairvalue-Calculator
EN DE

Ligand Pharmaceuticals Incorporated (LGND) Fair Value & Analysis

Healthcare · US · Market cap $4.7B

Price$279.44
Fair Value$55.10
Upside-80.3%
Quality95/100
Evidence: High Range $35.11 – $126.21

Fair value as of: Jun 24, 2026

Analysis

Ligand Pharmaceuticals Incorporated (LGND) currently trades at $279.44, while our model-based Fair Value estimate is $55.10 — implying the stock looks roughly 80.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatri…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Ligand Pharmaceuticals Incorporated (LGND) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $55.10 versus a price of $279.44 — about −80% (overvalued). Model-based estimate, not financial advice.
What is the fair value of LGND?
Our 21-model fair value for Ligand Pharmaceuticals Incorporated is $55.10 (as of Jun 24, 2026), built from audited fundamentals. The current price is $279.44.
What is the quality score of LGND?
Ligand Pharmaceuticals Incorporated has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.